MX2016008771A - Determinantes de respuesta del cancer a la inmunoterapia. - Google Patents
Determinantes de respuesta del cancer a la inmunoterapia.Info
- Publication number
- MX2016008771A MX2016008771A MX2016008771A MX2016008771A MX2016008771A MX 2016008771 A MX2016008771 A MX 2016008771A MX 2016008771 A MX2016008771 A MX 2016008771A MX 2016008771 A MX2016008771 A MX 2016008771A MX 2016008771 A MX2016008771 A MX 2016008771A
- Authority
- MX
- Mexico
- Prior art keywords
- immunotherapy
- determinants
- cancer response
- cancer
- response
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461923183P | 2014-01-02 | 2014-01-02 | |
| US201462066034P | 2014-10-20 | 2014-10-20 | |
| US201462072893P | 2014-10-30 | 2014-10-30 | |
| PCT/US2014/072125 WO2015103037A2 (en) | 2014-01-02 | 2014-12-23 | Determinants of cancer response to immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016008771A true MX2016008771A (es) | 2016-12-20 |
Family
ID=53494217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016008771A MX2016008771A (es) | 2014-01-02 | 2014-12-23 | Determinantes de respuesta del cancer a la inmunoterapia. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20160326597A1 (enExample) |
| EP (1) | EP3090066A4 (enExample) |
| JP (1) | JP2017504324A (enExample) |
| KR (1) | KR20160102314A (enExample) |
| CN (1) | CN106164289A (enExample) |
| AU (1) | AU2014374020A1 (enExample) |
| BR (1) | BR112016015399A2 (enExample) |
| CA (1) | CA2935214A1 (enExample) |
| CL (1) | CL2016001708A1 (enExample) |
| MX (1) | MX2016008771A (enExample) |
| PE (1) | PE20161344A1 (enExample) |
| PH (1) | PH12016501329A1 (enExample) |
| RU (1) | RU2707530C2 (enExample) |
| SG (2) | SG10201805674YA (enExample) |
| WO (1) | WO2015103037A2 (enExample) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9732131B2 (en) | 2006-02-27 | 2017-08-15 | Calviri, Inc. | Identification and use of novopeptides for the treatment of cancer |
| EP4098278A1 (en) | 2014-11-13 | 2022-12-07 | The Johns Hopkins University | Checkpoint blockade and microsatellite instability |
| MA40737A (fr) * | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| WO2016146143A1 (en) | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| WO2016164833A1 (en) | 2015-04-08 | 2016-10-13 | Nantomics, Llc | Cancer neoepitopes |
| RU2719033C2 (ru) * | 2015-04-23 | 2020-04-16 | Нантомикс, Ллс | Способ получения фармацевтического агента для иммунотерапии рака |
| EP3294324A1 (en) | 2015-05-13 | 2018-03-21 | Agenus Inc. | Vaccines for treatment and prevention of cancer |
| GB201516047D0 (en) * | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
| AU2016339924B2 (en) * | 2015-10-12 | 2020-01-02 | Nantomics, Llc | Compositions and methods for viral cancer neoepitopes |
| CA3003251A1 (en) * | 2015-10-12 | 2017-04-20 | Nantomics, Llc | Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors |
| EP3362929B1 (en) | 2015-10-12 | 2020-08-12 | Nantomics, LLC | Viral neoepitopes and uses thereof |
| CN108348588B (zh) * | 2015-10-23 | 2023-01-13 | 诺华股份有限公司 | 用于导出视野中呈现的选定细胞的生物标志物阳性百分比值的方法 |
| TWI733719B (zh) | 2015-12-07 | 2021-07-21 | 美商河谷控股Ｉｐ有限責任公司 | 改善的組合物及用於新表位之病毒遞送的方法及其應用 |
| KR102883915B1 (ko) | 2015-12-16 | 2025-11-18 | 시애틀 프로젝트 코포레이션 | 신생항원 동정, 제조, 및 용도 |
| WO2017118702A1 (en) * | 2016-01-08 | 2017-07-13 | Vaccibody As | Neoepitope rna cancer vaccine |
| JP2019511903A (ja) | 2016-02-19 | 2019-05-09 | ナント ホールディングス アイピー エルエルシーＮａｎｔ Ｈｏｌｄｉｎｇｓ ＩＰ， ＬＬＣ | 免疫原性調節の方法 |
| CN109196121B (zh) | 2016-02-29 | 2022-01-04 | 基因泰克公司 | 用于癌症的治疗和诊断方法 |
| CN109476731A (zh) * | 2016-02-29 | 2019-03-15 | 基础医药有限公司 | 治疗癌症的方法 |
| CN109072227A (zh) | 2016-03-15 | 2018-12-21 | 组库创世纪株式会社 | 用于免疫治疗的监测和诊断及治疗剂的设计 |
| PT3429618T (pt) * | 2016-03-16 | 2024-04-02 | Amal Therapeutics Sa | Combinação de um modulador de ponto de controlo imunitário e um complexo que compreende um péptido de penetração celular, uma carga e um agonistra peptídico de tlr para utilização em medicina |
| KR20190017950A (ko) * | 2016-06-10 | 2019-02-20 | 아이오 테라퓨틱스, 인크. | 암 면역요법을 위한 수용체 선택적 레티노이드 및 렉시노이드 화합물 및 면역 조절제 |
| US20190247435A1 (en) * | 2016-06-29 | 2019-08-15 | The Johns Hopkins University | Neoantigens as targets for immunotherapy |
| IL265479B (en) | 2016-09-21 | 2022-09-01 | Amal Therapeutics Sa | A fusion containing a cell-penetrating peptide, a multiple epitope, and a peptide tlr agonist for cancer therapy |
| EP3516081A4 (en) * | 2016-09-23 | 2020-07-29 | Memorial Sloan Kettering Cancer Center | DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY |
| EP3523451A1 (en) * | 2016-10-06 | 2019-08-14 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| EP3548897A4 (en) | 2016-12-01 | 2020-08-12 | Nantomics, LLC | PRESENTATION AND TREATMENT OF TUMOR ANTIGENICITY |
| WO2018112449A2 (en) | 2016-12-16 | 2018-06-21 | Nant Holdings Ip, Llc | Live cell imaging systems and methods to validate triggering of immune response |
| US20190369096A1 (en) * | 2017-01-13 | 2019-12-05 | Nantbio, Inc. | Validation of neoepitope-based treatment |
| CA3050109A1 (en) | 2017-01-18 | 2018-07-26 | Ichan School Of Medicine At Mount Sinai | Neoantigens and uses thereof for treating cancer |
| WO2018146128A1 (en) * | 2017-02-07 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy |
| AU2018234821A1 (en) * | 2017-03-17 | 2019-09-26 | Nantomics, Llc | Liquid biopsy for cfRNA |
| WO2018183928A1 (en) * | 2017-03-31 | 2018-10-04 | Bristol-Myers Squibb Company | Methods of treating tumor |
| EP3631471A4 (en) | 2017-05-30 | 2021-06-30 | Nant Holdings IP, LLC | Circulating tumor cell enrichment using neoepitopes |
| CN110996970A (zh) | 2017-06-02 | 2020-04-10 | 亚利桑那州立大学董事会 | 创建个性化癌症疫苗的方法 |
| US11322226B2 (en) * | 2017-06-13 | 2022-05-03 | Bostongene Corporation | Systems and methods for generating, visualizing and classifying molecular functional profiles |
| GB201710815D0 (en) * | 2017-07-05 | 2017-08-16 | Francis Crick Inst Ltd | Method |
| US12025615B2 (en) | 2017-09-15 | 2024-07-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of classifying response to immunotherapy for cancer |
| KR20200059243A (ko) | 2017-09-20 | 2020-05-28 | 리제너론 파마슈티칼스 인코포레이티드 | 패신저 유전자 돌연변이 부담이 높은 종양을 가진 환자에 대한 면역 치료요법 |
| US12474340B2 (en) | 2017-09-25 | 2025-11-18 | Nant Holdings Ip, Llc | Validation of neoepitope presentation |
| AU2018338441B2 (en) * | 2017-09-25 | 2025-08-14 | Memorial Sloan Kettering Cancer Center | Tumor mutational load and checkpoint immunotherapy |
| WO2019075112A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS |
| WO2019075468A1 (en) | 2017-10-15 | 2019-04-18 | Bristol-Myers Squibb Company | TUMOR TREATMENT METHODS |
| WO2019090156A1 (en) | 2017-11-03 | 2019-05-09 | Guardant Health, Inc. | Normalizing tumor mutation burden |
| CN111566484A (zh) * | 2017-11-09 | 2020-08-21 | 宾夕法尼亚大学董事会 | 细胞外囊泡蛋白及其在癌症诊断、预测对疗法的反应和治疗中的用途 |
| KR20260008173A (ko) | 2017-11-22 | 2026-01-15 | 시애틀 프로젝트 코포레이션 | 신생항원에 대한 접합 에피토프 제시 감소 |
| EP3622522A1 (en) | 2017-12-01 | 2020-03-18 | Illumina, Inc. | Methods and systems for determining somatic mutation clonality |
| CN108009400B (zh) * | 2018-01-11 | 2018-07-06 | 至本医疗科技（上海）有限公司 | 全基因组肿瘤突变负荷预测方法、设备以及存储介质 |
| US11414698B2 (en) * | 2018-03-22 | 2022-08-16 | Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi | Method of quantifying mutant allele burden of target gene |
| KR20210005646A (ko) | 2018-04-26 | 2021-01-14 | 아게누스 인코포레이티드 | 열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법 |
| AU2019310041B2 (en) | 2018-07-23 | 2025-11-20 | Guardant Health, Inc. | Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage |
| SG11202101400UA (en) | 2018-08-31 | 2021-03-30 | Guardant Health Inc | Microsatellite instability detection in cell-free dna |
| CN109371005B (zh) * | 2018-11-12 | 2022-09-30 | 上海市东方医院（同济大学附属东方医院） | 一种hla-0201限制性padi4表位多肽及其应用 |
| CN113194995A (zh) * | 2018-12-12 | 2021-07-30 | 免疫医疗有限责任公司 | 基于血液的肿瘤突变负荷预测非小细胞肺癌的总存活 |
| EP3899019A4 (en) * | 2018-12-21 | 2022-10-05 | Agency for Science, Technology and Research | METHOD OF PREDICTING THE BENEFITS OF IMMUNE CHECKPOINT INHIBITION THERAPY |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020206127A1 (en) | 2019-04-05 | 2020-10-08 | Illumina, Inc. | Quantitative score of hla diversity |
| JP2022533480A (ja) * | 2019-05-24 | 2022-07-22 | エディフィス ヘルス，インコーポレーテッド | 癌免疫療法のためのプレシジョンメディシン法 |
| EP4038222A4 (en) | 2019-10-02 | 2023-10-18 | Arizona Board of Regents on behalf of Arizona State University | Methods and compositions for identifying neoantigens for use in treating and preventing cancer |
| NL2024107B1 (en) * | 2019-10-26 | 2021-07-19 | Vitroscan B V | Compositions for Patient Specific Immunotherapy |
| CN111088349B (zh) * | 2020-02-14 | 2023-04-28 | 深圳市宝安区妇幼保健院 | Kir3dl1基因分型引物组及其应用 |
| EP4127243B1 (en) * | 2020-03-23 | 2023-11-22 | Koninklijke Philips N.V. | Prediction of radiotherapy response for prostate cancer subject based on immune checkpoint genes |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4000596A1 (en) * | 2020-11-17 | 2022-05-25 | The Boots Company plc | Tetrapeptide and compositions comprising tetrapeptides |
| EP4000595A1 (en) * | 2020-11-17 | 2022-05-25 | The Boots Company plc | Tetrapeptide and compositions comprising tetrapeptides |
| US20240192195A1 (en) * | 2021-04-10 | 2024-06-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | A multiomic approach to modeling of gene regulatory networks in multiple myeloma |
| EP4392140A1 (en) | 2021-08-24 | 2024-07-03 | BioNTech SE | In vitro transcription technologies |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| CN122003713A (zh) | 2023-04-12 | 2026-05-08 | 西奈山伊坎医学院 | 用于选择个性化新抗原疫苗的计算方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9826143D0 (en) * | 1998-11-27 | 1999-01-20 | Ludwig Inst Cancer Res | Tumour rejection antigens |
| US9222938B2 (en) * | 2001-12-04 | 2015-12-29 | Michael Tainsky | Neoepitope detection of disease using protein arrays |
| AU2005302459A1 (en) * | 2004-10-29 | 2006-05-11 | University Of Southern California | Combination cancer immunotherapy with co-stimulatory molecules |
| US20100099090A1 (en) * | 2007-03-05 | 2010-04-22 | Bristol-Mayers Squibb Company | Biomarkers and methods for determining sensitivity to ctla-4 antagonists |
| KR102095670B1 (ko) * | 2010-05-14 | 2020-03-31 | 더 제너럴 하스피톨 코포레이션 | 종양 특이적 신생항원을 확인하는 조성물 및 방법 |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| WO2012159643A1 (en) * | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
-
2014
- 2014-12-23 SG SG10201805674YA patent/SG10201805674YA/en unknown
- 2014-12-23 US US15/109,464 patent/US20160326597A1/en not_active Abandoned
- 2014-12-23 EP EP14876694.2A patent/EP3090066A4/en not_active Withdrawn
- 2014-12-23 CN CN201480075287.2A patent/CN106164289A/zh active Pending
- 2014-12-23 AU AU2014374020A patent/AU2014374020A1/en not_active Abandoned
- 2014-12-23 SG SG11201605432RA patent/SG11201605432RA/en unknown
- 2014-12-23 CA CA2935214A patent/CA2935214A1/en not_active Abandoned
- 2014-12-23 MX MX2016008771A patent/MX2016008771A/es unknown
- 2014-12-23 BR BR112016015399A patent/BR112016015399A2/pt not_active IP Right Cessation
- 2014-12-23 WO PCT/US2014/072125 patent/WO2015103037A2/en not_active Ceased
- 2014-12-23 KR KR1020167021093A patent/KR20160102314A/ko not_active Withdrawn
- 2014-12-23 PE PE2016000989A patent/PE20161344A1/es unknown
- 2014-12-23 JP JP2016544613A patent/JP2017504324A/ja active Pending
- 2014-12-23 RU RU2016131207A patent/RU2707530C2/ru not_active IP Right Cessation
-
2016
- 2016-07-01 CL CL2016001708A patent/CL2016001708A1/es unknown
- 2016-07-04 PH PH12016501329A patent/PH12016501329A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20160326597A1 (en) | 2016-11-10 |
| EP3090066A4 (en) | 2017-08-30 |
| PH12016501329A1 (en) | 2016-10-03 |
| SG11201605432RA (en) | 2016-07-28 |
| BR112016015399A2 (pt) | 2017-10-24 |
| RU2707530C2 (ru) | 2019-11-27 |
| WO2015103037A3 (en) | 2015-11-05 |
| KR20160102314A (ko) | 2016-08-29 |
| CL2016001708A1 (es) | 2017-03-17 |
| CA2935214A1 (en) | 2015-07-09 |
| SG10201805674YA (en) | 2018-08-30 |
| CN106164289A (zh) | 2016-11-23 |
| AU2014374020A1 (en) | 2016-08-18 |
| JP2017504324A (ja) | 2017-02-09 |
| WO2015103037A2 (en) | 2015-07-09 |
| RU2016131207A (ru) | 2018-02-07 |
| PE20161344A1 (es) | 2016-12-23 |
| RU2016131207A3 (enExample) | 2018-06-22 |
| EP3090066A2 (en) | 2016-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016001708A1 (es) | Determinantes de respuesta del cáncer a la inmunoterapia | |
| EP4393546A3 (en) | Determinants of cancer response to immunotherapy by pd-1 blockade | |
| CL2018002782A1 (es) | Apósito modificado | |
| MX2023007841A (es) | Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer. | |
| PH12016501763A1 (en) | Multispecific antibodies | |
| BR112016007401A2 (pt) | métodos e processos para avaliação não invasiva das variações genéticas | |
| MX2017001490A (es) | Combinaciones de farmacos para tratar mieloma multiple. | |
| MY165760A (en) | Absorbent article | |
| CO2017010808A2 (es) | Sistemas y métodos para la vigilancia activa del cancer de próstata | |
| MY187959A (en) | Reactor | |
| CL2017002653A1 (es) | Procedimiento y reactor para fijar arsénico. | |
| CL2016002535A1 (es) | Sistemas y métodos de sellado para miembros alargados | |
| EA201700060A1 (ru) | Терапевтическое средство для кератоконъюнктивальных расстройств | |
| MX2017001929A (es) | Activacion del factor x. | |
| TN2014000384A1 (fr) | نظام صوتي ذكي وآمن | |
| TN2014000468A1 (fr) | اختراع الة للف شباك مراكب الصيد البحري و تسهيل تحويلها من المركب الى رصيف الميناء ثم ارجاعها للمركب بعد القيام بعملية ترقيعها | |
| TN2014000355A1 (fr) | طريقة مبتكرة لتوفير الاضاءة العامة و المنزلية | |
| TN2014000377A1 (fr) | طائرة كهربائية كاتمة للصوت | |
| TN2014000388A1 (fr) | منظومة فيزيائية متجانسة كهربائية ميكانيكية مغناطيسية لتوليد الطاقة الكهربائية الحرة الايكولوجية المضاعفة | |
| TN2014000354A1 (fr) | جهاز مبتكر لتلقيح النخيل | |
| ITUA20161553A1 (it) | Impianto di erogazione del gas. | |
| UA114708U (uk) | Тяговий привід електробуса | |
| DK3032283T3 (da) | Tryktolerant seismisk kilde | |
| GT201400039S (es) | Diseño de bici-motocicleta | |
| GEAU201814047U (en) | Polymer composite |